DGIdb - ATORVASTATIN Drug Record

ATORVASTATIN chembl:CHEMBL1487 Approved

Alternate Names:

ATORVASTATIN
ZARATOR
TAHOR
PREVENCOR
SORTIS
CARDYL
LIPITOR
LCF872
(3R,5R)-7-[2-(4-FLUOROPHENYL)-3-PHENYL-4-(PHENYLCARBAMOYL)-5-(PROPAN-2-YL)-1H-PYRROL-1-YL]-3,5-DIHYDROXYHEPTANOIC ACID
chembl:CHEMBL1487
drugbank:01076
pubchem.compound:60823
rxcui:83367
chemidplus:134523-00-5

Drug Info:

Drug Indications	anticholesterolaemic agent
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antihypecholesterolemic agent
Year of Approval	1996
Drug Class	anticholesteremic agents
Drug Categories	heptanoic acids
Drug Categories	agents causing muscle toxicity
Drug Categories	bsep/abcb11 substrates
Drug Categories	cytochrome p-450 cyp2b6 inducers (strength unknown)
Drug Categories	cytochrome p-450 cyp2c19 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 cyp2c8 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 cyp2c9 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 cyp2d6 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 cyp3a substrates
Drug Categories	cytochrome p-450 cyp3a5 substrates
Drug Categories	cytochrome p-450 cyp3a7 substrates
Drug Categories	cytochrome p-450 enzyme inducers
Drug Categories	cytochrome p-450 enzyme inhibitors
Drug Categories	cytochrome p-450 substrates
Drug Categories	hypolipidemic agents indicated for hyperlipidemia
Drug Categories	lipid modifying agents, plain
Drug Categories	oatp1b1/slco1b1 inhibitors
Drug Categories	oatp1b3 substrates
Drug Categories	p-glycoprotein inhibitors
Drug Categories	p-glycoprotein substrates
Drug Categories	ugt1a1 substrates
Drug Categories	ugt1a3 substrates

(4 More Sources)

Publications:

Singer JB et al., 2007, Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients., J Lipid Res
Baxter et al., Selective activation of thyroid hormone signaling pathways by GC-1: a new approach to controlling cholesterol and body weight., Trends Endocrinol. Metab.
Maejima et al., 2004, Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell., Biochem. Biophys. Res. Commun.
Donnelly LA et al., 2008, A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study., Pharmacogenet Genomics
Krauss RM et al., 2008, Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment., Circulation
Thompson JF et al., 2005, An association study of 43 SNPs in 16 candidate genes with atorvastatin response., Pharmacogenomics J
Thompson JF et al., 2009, Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort., Circ Cardiovasc Genet
Polisecki E et al., 2008, Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER., Atherosclerosis
Jafari et al., 2003, Efficacy of alternate-day dosing versus daily dosing of atorvastatin., J. Cardiovasc. Pharmacol. Ther.
Chasman DI et al., 2004, Pharmacogenetic study of statin therapy and cholesterol reduction., JAMA
Cuevas A et al., 2016, HMGCR rs17671591 SNP Determines Lower Plasma LDL-C after Atorvastatin Therapy in Chilean Individuals., Basic Clin Pharmacol Toxicol
Davidson, 2002, Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia., Expert Opin Investig Drugs
Bösel et al., 2005, Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones., J. Neurochem.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Wassmann et al., 2001, Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase., Mol. Pharmacol.
Cho SK et al., 2012, The UGT1A3*2 polymorphism affects atorvastatin lactonization and lipid-lowering effect in healthy volunteers., Pharmacogenet Genomics
Kajinami K et al., 2004, Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin., Atherosclerosis
Srivastava A et al., 2010, Effect of genetic variant (rs11887534) in ABCG8 gene in coronary artery disease and response to atorvastatin therapy., Dis Markers
Shiffman D et al., 2010, Effect of pravastatin therapy on coronary events in carriers of the KIF6 719Arg allele from the cholesterol and recurrent events trial., Am J Cardiol
Iakoubova OA et al., 2008, Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials., J Am Coll Cardiol
Iakoubova OA et al., 2008, Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study., J Am Coll Cardiol
Iakoubova OA et al., 2010, KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study., Eur J Cardiovasc Prev Rehabil
Ruiz-Iruela C et al., 2018, KIF6 gene as a pharmacogenetic marker for lipid-lowering effect in statin treatment., PLoS One
Xu et al., 2002, Reduction of bFGF-induced smooth muscle cell proliferation and endothelin receptor mRNA expression by mevastatin and atorvastatin., Biochem. Pharmacol.
Planavila et al., 2005, Atorvastatin prevents peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) downregulation in lipopolysaccharide-stimulated H9c2 cells., Biochim. Biophys. Acta
Zineh et al., 2006, Atorvastatin effect on circulating and leukocyte-produced CD40 ligand concentrations in people with normal cholesterol levels: a pilot study., Pharmacotherapy
Puccetti L et al., 2010, Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study., Atherosclerosis
Korhonova M et al., 2015, Optical Isomers of Atorvastatin, Rosuvastatin and Fluvastatin Enantiospecifically Activate Pregnane X Receptor PXR and Induce CYP2A6, CYP2B6 and CYP3A4 in Human Hepatocytes., PLoS One
Chauvin et al., 2013, Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors., Clin Pharmacokinet
Hu et al., 2007, Induction of cyp1a1 is a nonspecific biomarker of aryl hydrocarbon receptor activation: results of large scale screening of pharmaceuticals and toxicants in vivo and in vitro., Mol. Pharmacol.
Oria de Suárez et al., 2006, [Effect of atorvastatin on Fas (CD95/Apo-1) expression in normal or ischemic brain]., An Med Interna
Ortego et al., 1999, Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells., Atherosclerosis
Pérez-Castrillón JL et al., 2008, Effect of the TNFalpha-308 G/A polymorphism on the changes produced by atorvastatin in bone mineral density in patients with acute coronary syndrome., Ann Nutr Metab
Sai K et al., 2016, A possible role for HLA-DRB1*04:06 in statin-related myopathy in Japanese patients., Drug Metab Pharmacokinet
Hubacek JA et al., 2009, Impact of apolipoprotein A5 variants on statin treatment efficacy., Pharmacogenomics
Gao Y et al., 2008, CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin., Eur J Clin Pharmacol
Burton et al., 2007, Clopidogrel-precipitated rhabdomyolysis in a stable heart transplant patient., Ann Pharmacother
Becker ML et al., 2010, Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy., Pharmacoepidemiol Drug Saf
Becker ML et al., 2013, Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy., Pharmacogenomics J
Prado Y et al., 2018, Gender-Specific Association Between ABCC2 -24C>T SNP and Reduction in Triglycerides in Chilean Patients Treated With Atorvastatin., Basic Clin Pharmacol Toxicol
Ruaño G et al., 2007, Physiogenomic association of statin-related myalgia to serotonin receptors., Muscle Nerve
Soehnlein et al., 2004, Atorvastatin induces tissue transglutaminase in human endothelial cells., Biochem. Biophys. Res. Commun.
Arazi SS et al., 2008, Atorvastatin effects on SREBF1a and SCAP gene expression in mononuclear cells and its relation with lowering-lipids response., Clin Chim Acta
Suh JW et al., 2014, Relationship between statin type and responsiveness to clopidogrel in patients treated with percutaneous coronary intervention: a subgroup analysis of the CILON-T trial., J Atheroscler Thromb
Wilke RA et al., 2005, Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage., Pharmacogenet Genomics
Willrich MA et al., 2008, CYP3A53A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia., Clin Chim Acta
Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
Zuccaro P et al., 2007, Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin., Pharmacol Res
Kivistö KT et al., 2004, Lipid-lowering response to statins is affected by CYP3A5 polymorphism., Pharmacogenetics
Drogari E et al., 2014, POR*28 SNP is associated with lipid response to atorvastatin in children and adolescents with familial hypercholesterolemia., Pharmacogenomics
Pérez-Castrillón JL et al., 2014, Polymorphisms of the farnesyl diphosphate synthase gene modulate bone changes in response to atorvastatin., Rheumatol Int
Olmos JM et al., 2012, Common allelic variants of the farnesyl diphosphate synthase gene influence the response of osteoporotic women to bisphosphonates., Pharmacogenomics J
Nakajima et al., 2006, Differential roles of MAP kinases in atorvastatin-induced VEGF release in cardiac myocytes., Life Sci.
Voora D et al., 2008, Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response., Circ Cardiovasc Genet
Frudakis TN et al., 2007, CYP2D6*4 polymorphism is associated with statin-induced muscle effects., Pharmacogenet Genomics
Dobreanu et al., 2007, Integrin expression on monocytes and lymphocytes in unstable angina short term effects of atorvastatin., Rom J Intern Med
Bartok et al., 2005, Atorvastatin reduces thrombin generation after percutaneous coronary intervention independent of soluble tissue factor., Thromb. Res.
Santos PC et al., 2014, The MYLIP p.N342S polymorphism is associated with response to lipid-lowering therapy in Brazilian patients with familial hypercholesterolemia., Pharmacogenet Genomics
Pérez-Castrillón JL et al., 2009, Atorvastatin and BMD in coronary syndrome. Role of Lys656Asn polymorphism of leptin receptor gene., Endocr J
Osman et al., 2006, Role of human valve interstitial cells in valve calcification and their response to atorvastatin., Circulation
Urbich et al., 2005, FOXO-dependent expression of the proapoptotic protein Bim: pivotal role for apoptosis signaling in endothelial progenitor cells., FASEB J.
Keskitalo JE et al., 2009, ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin., Clin Pharmacol Ther
Goebel et al., 2005, Atorvastatin affects interleukin-2 signaling by altering the lipid raft enrichment of the interleukin-2 receptor beta chain., J. Investig. Med.
Berk-Planken et al., 2003, Atorvastatin dose-dependently decreases hepatic lipase activity in type 2 diabetes: effect of sex and the LIPC promoter variant., Diabetes Care
Mega JL et al., 2009, Identification of genetic variants associated with response to statin therapy., Arterioscler Thromb Vasc Biol
Goicoechea et al., 2006, Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease., J. Am. Soc. Nephrol.
Kadam P et al., 2016, Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population., J Clin Pharm Ther
Wei KK et al., 2011, Interactions between CYP7A1 A-204C and ABCG8 C1199A polymorphisms on lipid lowering with atorvastatin., J Clin Pharm Ther
Hoenig MR et al., 2011, The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort., J Clin Lipidol
Chen et al., 2005, Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1., Drug Metab. Dispos.
Keskitalo JE et al., 2008, ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin., Clin Pharmacol Ther
Rebecchi IM et al., 2009, ABCB1 and ABCC1 expression in peripheral mononuclear cells is influenced by gene polymorphisms and atorvastatin treatment., Biochem Pharmacol
Fu R et al., 2008, Effect of statin therapy on plasma high-density lipoprotein-cholesterol levels is modified by paraoxonase 1 in Chinese patients with coronary heart disease., Clin Exp Pharmacol Physiol
Himbergen TM et al., 2005, The effect of statin therapy on plasma high-density lipoprotein cholesterol levels is modified by paraoxonase-1 in patients with familial hypercholesterolaemia., J Intern Med
Nagila A et al., 2009, Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status., Pharmacol Rep
Ghayour-Mobarhan et al., Heat shock protein antibody titers are reduced by statin therapy in dyslipidemic subjects: a pilot study., Angiology
van Venrooij FV et al., 2003, Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes., Diabetes Care
Mohrschladt MF et al., 2005, TaqIB polymorphism in CETP gene: the influence on incidence of cardiovascular disease in statin-treated patients with familial hypercholesterolemia., Eur J Hum Genet
Cerda A et al., 2010, Influence of SCARB1 polymorphisms on serum lipids of hypercholesterolemic individuals treated with atorvastatin., Clin Chim Acta
Raal et al., 2003, Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia., Atherosclerosis
Birnbaum et al., 2005, Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury., Cardiovasc. Res.
Hubacek JA et al., 2015, Association between polymorphism within the RYR2 receptor and development of statin-associated myalgia/myopathy in the Czech population., Eur J Intern Med
Lau et al., 2007, effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers., Clin. Pharmacol. Ther.
Potaczek DP et al., 2005, The angiotensin-converting enzyme gene insertion/deletion polymorphism and effects of quinapril and atorvastatin on haemostatic parameters in patients with coronary artery disease., Thromb Haemost
Pal et al., 2002, Cholesterol esters regulate apoB48 secretion in CaCo2 cells., Atherosclerosis
Forster et al., 2002, Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates., Atherosclerosis
Mohammadi et al., 1998, Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells., Arterioscler. Thromb. Vasc. Biol.
Miltiadous et al., 2005, Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia., Pharmacogenet. Genomics
Wilcox et al., 1999, Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin., J. Lipid Res.
Telford et al., 2003, Inhibition of both the apical sodium-dependent bile acid transporter and HMG-CoA reductase markedly enhances the clearance of LDL apoB., J. Lipid Res.
Burnett et al., 1999, The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs., Endocrinology
Tsimikas et al., 2004, High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial., Circulation
Chan et al., 2002, Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia., Diabetes
Taldone et al., 2008, Inhibition of dipeptidyl peptidase-IV (DPP-IV) by atorvastatin., Bioorg. Med. Chem. Lett.
García-García AB et al., 2005, Influence of microsomal triglyceride transfer protein promoter polymorphism -493 GT on fasting plasma triglyceride values and interaction with treatment response to atorvastatin in subjects with heterozygous familial hypercholesterolaemia., Pharmacogenet Genomics
Lin et al., 2008, Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2., Cancer Res.
Režen T et al., 2017, Rosuvastatin and Atorvastatin Are Ligands of the Human Constitutive Androstane Receptor/Retinoid X Receptor <i>α</i> Complex., Drug Metab Dispos

ATORVASTATIN CYP7A1

Interaction Score: 4.44

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16103896 15262185 26932749 21128988

Sources:
PharmGKB
ATORVASTATIN ABCG8

Interaction Score: 3.55

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16103896 15262185 20592455

Sources:
PharmGKB
ATORVASTATIN MYLIP

Interaction Score: 1.78

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25171759

Sources:
PharmGKB
ATORVASTATIN KIF6

Interaction Score: 1.33

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20403483 18222353 18222355 20215968 30304062

Sources:
PharmGKB
ATORVASTATIN SCAP

Interaction Score: 0.89

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18435918

Sources:
PharmGKB
ATORVASTATIN COQ2

Interaction Score: 0.89

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20347093

Sources:
PharmGKB
ATORVASTATIN HMGCR

Interaction Score: 0.63

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Details of the Assay for Interaction In vitro inhibition of HMG-CoA reductase

Specific Action of the Ligand Competitive

Endogenous Drug? False

PMIDs:
17563401 15109613 15474503 18815589 18332269 16103896 20031582 18261733 12808485 15199031 26408409 12769127 15748157 11752352

Sources:
TEND PharmGKB TdgClinicalTrial TTD DrugBank GuideToPharmacology
ATORVASTATIN LEPR

Interaction Score: 0.59

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19023160

Sources:
PharmGKB
ATORVASTATIN APOB

Interaction Score: 0.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11882317 12119202 9598838 15864114 10357840 12562847 10537160 15353498 12145148

Sources:
NCI
ATORVASTATIN SCARB1

Interaction Score: 0.44

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20064494

Sources:
PharmGKB
ATORVASTATIN HSPD1

Interaction Score: 0.44

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15678257

Sources:
NCI
ATORVASTATIN APOA5

Interaction Score: 0.44

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19530961

Sources:
PharmGKB
ATORVASTATIN PON1

Interaction Score: 0.36

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18430057 16238680 19904013

Sources:
PharmGKB
ATORVASTATIN CETP

Interaction Score: 0.3

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16103896 12663600 15856070

Sources:
PharmGKB
ATORVASTATIN SOAT1

Interaction Score: 0.25

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14644397

Sources:
NCI
ATORVASTATIN LIPC

Interaction Score: 0.25

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12547874

Sources:
NCI
ATORVASTATIN APOE

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16103896 19667110 20031582 17289397

Sources:
PharmGKB
ATORVASTATIN RYR2

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27839692 25753936

Sources:
PharmGKB
ATORVASTATIN ABCA1

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20031551

Sources:
PharmGKB
ATORVASTATIN MTTP

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15864113

Sources:
PharmGKB
ATORVASTATIN ITGAM

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18333374

Sources:
NCI
ATORVASTATIN PLAT

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17130267

Sources:
NCI
ATORVASTATIN TFPI

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15792677

Sources:
NCI
ATORVASTATIN POR

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25521355

Sources:
PharmGKB
ATORVASTATIN CD40LG

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17064201

Sources:
NCI
ATORVASTATIN CXCL10

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10559511

Sources:
NCI
ATORVASTATIN FDPS

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24311107 21151198

Sources:
PharmGKB
ATORVASTATIN UGT1A3

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22555810

Sources:
PharmGKB
ATORVASTATIN HTR3B

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17600820

Sources:
PharmGKB
ATORVASTATIN FAS

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16796407

Sources:
NCI
ATORVASTATIN FGF2

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12147302

Sources:
NCI
ATORVASTATIN TGM2

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15313180

Sources:
NCI
ATORVASTATIN BDKRB2

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ATORVASTATIN NR1I3

Interaction Score: 0.07

Interaction Types & Directionality:

ligand

Interaction Info:

PMIDs:
28536098

Sources:
DrugBank
ATORVASTATIN BGLAP

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16820635

Sources:
NCI
ATORVASTATIN IL2RA

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16207471

Sources:
NCI
ATORVASTATIN CYP3A5

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16103896 15900215 18727922 18695978 17289397 15284534

Sources:
PharmGKB
ATORVASTATIN HLA-DRB1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27839692

Sources:
PharmGKB
ATORVASTATIN AGTR1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11179461

Sources:
NCI PharmGKB
ATORVASTATIN ABCC2

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22186618 29178257

Sources:
PharmGKB
ATORVASTATIN AHR

Interaction Score: 0.05

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

PMIDs:
26366873 23703578 17327465

Sources:
DrugBank
ATORVASTATIN UGT2B7

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ATORVASTATIN LDLR

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ATORVASTATIN MAPK10

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16701707

Sources:
NCI
ATORVASTATIN SLCO2B1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ATORVASTATIN HDAC2

Interaction Score: 0.03

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
18381445

Sources:
DrugBank
ATORVASTATIN SLCO1B3

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ATORVASTATIN SLCO1B1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17192770

Sources:
NCI
ATORVASTATIN ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16103896 21392722 15616150 26932749 19802823 19238649 18851956

Sources:
NCI PharmGKB
ATORVASTATIN DPP4

Interaction Score: 0.03

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
18068977

Sources:
DrugBank
ATORVASTATIN CYP2C8

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ATORVASTATIN NOS1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15639473

Sources:
NCI
ATORVASTATIN ABCG2

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19474787

Sources:
PharmGKB
ATORVASTATIN HTR7

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17600820

Sources:
PharmGKB
ATORVASTATIN ACE

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16116691

Sources:
PharmGKB
ATORVASTATIN UGT1A1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ATORVASTATIN TNF

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18997459

Sources:
PharmGKB
ATORVASTATIN PIK3CG

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15824087

Sources:
NCI
ATORVASTATIN PPARD

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16139565

Sources:
NCI
ATORVASTATIN NR1I2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ATORVASTATIN CYP3A4

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18528690 17200431 19802823

Sources:
NCI PharmGKB
ATORVASTATIN CYP2C19

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24140730

Sources:
PharmGKB
ATORVASTATIN CYP2D6

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17700359

Sources:
PharmGKB
ATORVASTATIN CYP2C9

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB

DrugBank: DB01076

Version: 5.1.7

Alternate Names:

Lipotropic Drug Brand

Liprimar Drug Brand

Liptruzet Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Categories agents causing muscle toxicity

Publications:

Korhonova M et al., 2015, Optical Isomers of Atorvastatin, Rosuvastatin and Fluvastatin Enantiospecifically Activate Pregnane X Receptor PXR and Induce CYP2A6, CYP2B6 and CYP3A4 in Human Hepatocytes., PLoS One

Chauvin et al., 2013, Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors., Clin Pharmacokinet

Hu et al., 2007, Induction of cyp1a1 is a nonspecific biomarker of aryl hydrocarbon receptor activation: results of large scale screening of pharmaceuticals and toxicants in vivo and in vitro., Mol. Pharmacol.

TEND: ATORVASTATIN
- Version: 01-August-2011
Alternate Names:

ATORVASTATIN Primary Drug Name

Drug Info:

Drug Class anticholesteremic agents

Year of Approval 1996

Publications:
TdgClinicalTrial: ATORVASTATIN
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antihypecholesterolemic agent

Drug Class Small Molecule

FDA Approval approved

Publications:

NCI: ATORVASTATIN

Version: 14-September-2017

Alternate Names:

C28837 NCI drug code

Drug Info:

Publications:

Planavila et al., 2005, Atorvastatin prevents peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) downregulation in lipopolysaccharide-stimulated H9c2 cells., Biochim. Biophys. Acta

Soehnlein et al., 2004, Atorvastatin induces tissue transglutaminase in human endothelial cells., Biochem. Biophys. Res. Commun.

Wassmann et al., 2001, Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase., Mol. Pharmacol.

PharmGKB: atorvastatin

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Cho SK et al., 2012, The UGT1A3*2 polymorphism affects atorvastatin lactonization and lipid-lowering effect in healthy volunteers., Pharmacogenet Genomics

Thompson JF et al., 2005, An association study of 43 SNPs in 16 candidate genes with atorvastatin response., Pharmacogenomics J

Kajinami K et al., 2004, Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin., Atherosclerosis

GuideToPharmacology: 135649972
- Version: 29-September-2020
Alternate Names:

ATORVASTATIN GuideToPharmacology Ligand Name

Drug Info:

Publications:
TTD: Atorvastatin
- Version: 2020.06.01
Alternate Names:

D01QIN TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1487
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Details of the Assay for Interaction	In vitro inhibition of HMG-CoA reductase
Specific Action of the Ligand	Competitive
Endogenous Drug?	False

Drug Type	small molecule
Drug Groups	approved
Drug Categories	agents causing muscle toxicity

ATORVASTATIN Drug Record

ATORVASTATIN chembl:CHEMBL1487 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16103896 15262185 26932749 21128988

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16103896 15262185 20592455

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25171759

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20403483 18222353 18222355 20215968 30304062

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18435918

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20347093

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Details of the Assay for Interaction In vitro inhibition of HMG-CoA reductase Specific Action of the Ligand Competitive Endogenous Drug? False

PMIDs: 17563401 15109613 15474503 18815589 18332269 16103896 20031582 18261733 12808485 15199031 26408409 12769127 15748157 11752352

Sources: TEND PharmGKB TdgClinicalTrial TTD DrugBank GuideToPharmacology

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19023160

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11882317 12119202 9598838 15864114 10357840 12562847 10537160 15353498 12145148

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20064494

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15678257

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19530961

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18430057 16238680 19904013

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16103896 12663600 15856070

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 14644397

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12547874

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16103896 19667110 20031582 17289397

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27839692 25753936

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20031551

Interaction Types & Directionality:

n/a

PMIDs:
16103896 15262185 26932749 21128988

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16103896 15262185 20592455

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25171759

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20403483 18222353 18222355 20215968 30304062

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18435918

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20347093

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Details of the Assay for Interaction In vitro inhibition of HMG-CoA reductase

Specific Action of the Ligand Competitive

Endogenous Drug? False

PMIDs:
17563401 15109613 15474503 18815589 18332269 16103896 20031582 18261733 12808485 15199031 26408409 12769127 15748157 11752352

Sources:
TEND PharmGKB TdgClinicalTrial TTD DrugBank GuideToPharmacology

Interaction Types & Directionality:

n/a

PMIDs:
19023160

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
11882317 12119202 9598838 15864114 10357840 12562847 10537160 15353498 12145148

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
20064494

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15678257

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
19530961

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18430057 16238680 19904013

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16103896 12663600 15856070

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
14644397

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
12547874

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16103896 19667110 20031582 17289397

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27839692 25753936

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20031551

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15864113

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18333374

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
17130267

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15792677

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
25521355

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17064201

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
10559511

Sources:
NCI

Interaction Types & Directionality:

n/a